Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
32.39
-0.60 (-1.82%)
At close: Apr 28, 2026, 4:00 PM EDT
32.60
+0.21 (0.65%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Viking Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Viking Therapeutics stock have an average target of 94.44, with a low estimate of 38 and a high estimate of 125. The average target predicts an increase of 191.57% from the current stock price of 32.39.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 23, 2026.
Analyst Ratings
The average analyst rating for Viking Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 5 | 5 |
| Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +214.91% | Mar 23, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $106 → $107 | Strong Buy | Maintains | $106 → $107 | +230.35% | Nov 12, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $106 | Strong Buy | Initiates | $106 | +227.26% | Oct 29, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $80 → $75 | Buy | Maintains | $80 → $75 | +131.55% | Oct 24, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $98 → $102 | Buy | Maintains | $98 → $102 | +214.91% | Oct 23, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.39
from -3.19
EPS Next Year
-4.67
from -4.39
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.89 | -3.03 | ||||||
| Avg | -4.39 | -4.67 | ||||||
| Low | -7.27 | -8.34 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.